Pharma giant takes equity stakes and co-development deals with Korean aesthetic brands to address GLP-1 side effects.
Eli Lilly has begun taking equity stakes in and co-developing products with Korean beauty companies to address aesthetic complications from Mounjaro (tirzepatide) and other GLP-1 agonists. The move signals that pharma is now directly investing in the aesthetic correction market—not just tolerating it.
GLP-1 users experience rapid subcutaneous fat loss, skin laxity, and facial volume depletion—the "Mounjaro face" phenomenon. Lilly's K-beauty partnerships aim to develop topical and procedural solutions that can be marketed alongside the drug itself. This is vertical integration into aesthetics by a major pharmaceutical player.
Lilly takes equity stakes in K-beauty to address Mounjaro face
For medspa owners, this matters because it legitimizes the GLP-1 correction market and signals that major pharma sees aesthetic practices as distribution channels for ancillary products. Expect Lilly and other GLP-1 manufacturers to launch branded skincare lines, partner with device makers on body-contouring protocols, and possibly offer rebate programs tied to GLP-1 patient referrals.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
